News

Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has acquired formulation development specialist Co-Formulate Limited. Quotient Clinical has brought innovation to the drug development process through its unique Translational Pharmaceutics platform, which challenges the conventional industry approach by integrating formulation development, real-time GMP manufacturing and clinical testing. The acquisition of Co-Formulate reinforces and […]

Quotient Clinical, the Translational Pharmaceutics® company, has announced that it has been acquired by specialist healthcare investor GHO Capital, with financial details of the transaction remaining undisclosed.

Quotient Clinical, the Translational Pharmaceutics® company, has expanded its data sciences services in response to increasing customer demand, doubling the footprint of its facilities in Edinburgh and Nottingham, as well as increasing its specialist headcount and appointing a new Vice President.

Quotient Clinical, the Translational Pharmaceutics® Company, has announced a significant expansion of its pharmaceutical sciences capabilities, doubling capacity through the acquisition of a second GMP manufacturing facility and the construction of new formulation development and pharmaceutical analysis laboratories. The new laboratories, based within the company’s existing Nottingham facility, were commissioned in response to an increasing […]

Quotient Clinical, the Translational Pharmaceutics® Company, announces another strong year of progress and growth. Quotient’s Translational Pharmaceutics platform has been adopted by more than 30 new customers – ranging from top 20 pharma companies to emerging biotech organizations – contributing to a year-on-year increase in revenue of 24%, with similar growth levels anticipated in the next 12 months.

Quotient Clinical, the Translational Pharmaceutics® Company, has announced contract wins for three further OncoADME programs to support clinical mass balance/ADME investigations in cancer patients. Two of the programs will be undertaken on behalf of US-based biotech organizations and the third is for a top 10 global pharmaceutical company.